Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI

被引:454
作者
Schoepfer, Alain M. [1 ,2 ]
Beglinger, Christoph [3 ]
Straumann, Alex [3 ]
Trummler, Michael [4 ]
Vavricka, Stephan R. [3 ]
Bruegger, Lukas E. [2 ]
Seibold, Frank [2 ]
机构
[1] McMaster Univ, Farncombe Family Inst Digest Hlth Res, Hamilton, ON L8N 3Z5, Canada
[2] Univ Hosp Bern, Inselspital, Dept Visceral Surg & Med, CH-3010 Bern, Switzerland
[3] Univ Basel Hosp, Dept Gastroenterol, CH-4031 Basel, Switzerland
[4] Bioanalyt Med Labs, Luzern, Switzerland
基金
瑞士国家科学基金会;
关键词
INFLAMMATORY-BOWEL-DISEASE; QUALITY-OF-LIFE; ULCERATIVE-COLITIS; INTESTINAL INFLAMMATION; MAINTENANCE TREATMENT; ACTIVITY INDEX; INFLIXIMAB; LACTOFERRIN; HOSPITALIZATIONS; PERFORMANCE;
D O I
10.1038/ajg.2009.545
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Studies evaluating the correlation between the widely used Simple Endoscopic Score for Crohn's disease (SES-CD) and noninvasive markers are scarce. The aim of this study was to evaluate the correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and the Crohn's disease activity index (CDAI). METHODS: Crohn's disease patients undergoing complete ileocolonoscopy were prospectively enrolled and scored independently according to the SES-CD and the CDAI. SES-CD was defined as follows: inactive 0-3; mild 4-10; moderate 11-19; and high >= 20. RESULTS: Values in CD patients (n=140 ileocolonoscopies) compared with controls (n=43) are as follows: calprotectin, 334 +/- 322 vs. 18 +/- 5 mu g/g; CRP, 26 +/- 29 vs. 3 +/- 2 mg/l; and blood leukocytes, 9.1 +/- 3.4 vs. 5.4 +/- 1.9 g/l (all P < 0.001). The SES-CD correlated closest with calprotectin (Spearman's rank correlation coefficient r=0.75), followed by CRP (r=0.53), blood leukocytes (r=0.42), and the CDAI (r=0.38). Calprotectin was the only marker that could discriminate inactive endoscopic disease from mild activity (104 +/- 138 vs. 231 +/- 244 mu g/g, P<0.001), mild from moderate activity (231 +/- 244 vs. 395 +/- 256 mu g/g, P=0.008), and moderate from high activity (395 +/- 256 vs. 718 +/- 320 mu g/g, P<0.001). The overall accuracy for the detection of endoscopically active disease was 87% for calprotectin (cutoff 70 mu g/g), 66% for elevated CRP, 54% for blood leukocytosis, and 40% for the CDAI >= 150. CONCLUSIONS: Fecal calprotectin correlated closest with SES-CD, followed by CRP, blood leukocytes, and the CDAI. Furthermore, fecal calprotectin was the only marker that reliably discriminated inactive from mild, moderate, and highly active disease, which underlines its usefulness for activity monitoring. Am J Gastroenterol 2010; 105: 162-169; doi:10.1038/ajg.2009.545; published online 15 September 2009
引用
收藏
页码:162 / 169
页数:8
相关论文
共 30 条
[1]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[2]   Infliximab use in Crohn's disease [J].
Bewtra, M ;
Lichtenstein, GR .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (04) :589-599
[3]   Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[4]   Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease [J].
Canani, R. Berni ;
Terrin, G. ;
Rapacciuolo, L. ;
Miele, E. ;
Siani, M. C. ;
Puzone, C. ;
Cosenza, L. ;
Staiano, A. ;
Troncone, R. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (07) :547-553
[5]   Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels [J].
Carlson, CS ;
Aldred, SF ;
Lee, PK ;
Tracy, RP ;
Schwartz, SM ;
Rieder, M ;
Liu, KA ;
Williams, OD ;
Iribarren, C ;
Lewis, EC ;
Fornage, M ;
Boerwinkle, E ;
Gross, M ;
Jaquish, C ;
Nickerson, DA ;
Myers, RM ;
Siscovick, DS ;
Reiner, AP .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (01) :64-77
[6]   Acceptance of colonoscopy requires more than test tolerance [J].
Condon, Amanda ;
Graff, Lesley ;
Elliot, Lawrence ;
Ilnyckyj, Alexandra .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 22 (01) :41-47
[7]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[8]   ARE ACTIVITY INDEXES HELPFUL IN ASSESSING ACTIVE INTESTINAL INFLAMMATION IN CROHNS-DISEASE [J].
CRAMABOHBOUTH, G ;
PENA, AS ;
BIEMOND, I ;
VERSPAGET, HW ;
BLOK, D ;
ARNDT, JW ;
WETERMAN, IT ;
PAUWELS, EKJ ;
LAMERS, CBHW .
GUT, 1989, 30 (09) :1236-1240
[9]   Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].
Daperno, M ;
D'Haens, G ;
Van Assche, G ;
Baert, F ;
Bulois, P ;
Maunoury, V ;
Sostegni, R ;
Rocca, R ;
Pera, A ;
Gevers, A ;
Mary, JY ;
Colombel, JF ;
Rutgeerts, P .
GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512
[10]   Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial [J].
Hanauer, SB ;
Sandborn, WJ ;
Rutgeerts, P ;
Fedorak, RN ;
Lukas, M ;
Macintosh, D ;
Panaccione, R ;
Wolf, D ;
Pollack, P .
GASTROENTEROLOGY, 2006, 130 (02) :323-332